m6A-centered Drug Response Information

General Information of the Drug (ID: M6APDG00226)
Name
L-carnitine
Synonyms
(-)-(R)-3-Hydroxy-4-(trimethylammonio)butyrate; (-)-Carnitine; (-)-L-Carnitin; (-)-L-Carnitine; (3-Carboxy-2-hydroxypropyl)trimethyl-ammonium hydroxide, inner salt; (3R)-3-hydroxy-4-(trimethylammonio)butanoate; (3R)-3-hydroxy-4-(trimethylazaniumyl)butanoate; (L-3-Carboxy-2-hydroxypropyl)trimethylammonium hydroxide, inner salt; (R)-(3-Carboxy-2-hydroxypropyl)trimethylammonium hydroxide; (R)-(3-Carboxy-2-hydroxypropyl)trimethylammonium hydroxide, inner salt; (R)-3-Hydroxy-4-(trimethylammonio)butyrate; (R)-3-Hydroxy-4-trimethylammoniobutyrate; (R)-Carnitine; 1-CARNITINE; 1-Propanaminium, 3-carboxy-2-hydroxy-N,N,N-trimethyl-, hydroxide, inner salt; 1-Propanaminium, 3-carboxy-2-hydroxy-N,N,N-trimethyl-, inner salt, (2R)-(9CI); 3-Carboxy-2-hydroxy-N,N,N-trimethyl-1-propanaminium hydroxide, inner salt; 3-Carboxy-2-hydroxy-N,N,N-trimethyl-1-propanaminium hydroxide, innersalt; 3-carboxy-2-hydroxy-N,N,N-trimethyl-1-propanaminium; Ammonium, (3-carboxy-2-hydroxypropyl)trimethyl-, hydroxide, inner salt, L-(8CI); Ammonium, (3-carboxy-2-hydroxypropyl)trimethyl-, hydroxide,inner salt; Bicarnesine; C-1985; Carnicor; Carniking; Carniking 50; Carnilean; Carnitene; Carnitine; Carnitine (L-form); Carnitolo; Carnitor; Carnitor (TN); Carnovis; Carrier; DRG-0211; Gamma-Trimethyl-ammonium-beta-hydroxybutirate; Gamma-Trimethyl-beta-hydroxybutyrobetaine; Karnitin; L-(-)-Carnitine; L-Carnitine inner salt; L-carnitine Base; L-gamma-trimethyl-beta-hydroxybutyrobetaine; Lefcar; Levocarnitina; Levocarnitina [Spanish]; Levocarnitine; Levocarnitine (JAN/USP/INN); Levocarnitine [USAN:INN]; Levocarnitinum; Levocarnitinum [Latin]; Metina; R-(-)-3-hydroxy-4-trimethylaminobutyrate; ST 198; Vitamin B T; Vitamin BT
    Click to Show/Hide
Status
Approved
Structure
Formula
C7H15NO3
InChI
1S/C7H15NO3/c1-8(2,3)5-6(9)4-7(10)11/h6,9H,4-5H2,1-3H3/t6-/m1/s1
InChIKey
PHIQHXFUZVPYII-ZCFIWIBFSA-N
PubChem CID
10917
VARIDT Drug ID
DR00255
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Alanine/serine/cysteine/threonine transporter 2 (SLC1A5)
Fat mass and obesity-associated protein (FTO)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Alanine/serine/cysteine/threonine transporter 2 (SLC1A5) is a therapeutic target for L-carnitine. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of L-carnitine through regulating the expression of Alanine/serine/cysteine/threonine transporter 2 (SLC1A5). [1], [2]
References
Ref 1 The m(6)A RNA demethylase FTO is a HIF-independent synthetic lethal partner with the VHL tumor suppressor. Proc Natl Acad Sci U S A. 2020 Sep 1;117(35):21441-21449. doi: 10.1073/pnas.2000516117. Epub 2020 Aug 19.
Ref 2 A polarized localization of amino acid/carnitine transporter B(0,+) (ATB(0,+)) in the blood-brain barrier. Biochem Biophys Res Commun. 2008 Nov 14;376(2):267-70. doi: 10.1016/j.bbrc.2008.08.122. Epub 2008 Sep 2.